Ignite Creation Date:
2024-05-05 @ 11:34 PM
Last Modification Date:
2024-10-26 @ 10:35 AM
Study NCT ID:
NCT01360021
Status:
COMPLETED
Last Update Posted:
2014-03-11
First Post:
2011-05-19
Brief Title:
New Breath Actuated MDI Symbicort Compared to Symbicort pMDI and Budesonide pMDI for 12 Weeks Twice a Day
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
A 12-week Double-blind Randomized Multi-centre Parallel-group Study Evaluating the Efficacy Safety and Patient Use User Study of Symbicort BudesonideFormoterol Breath Actuated Metered Dose Inhaler BA MDI 2x16045 μg Twice Daily Compared With Symbicort BudesonideFormoterol AC Actuation Counter pMDI 2x16045 μg Twice Daily and Budesonide AC pMDI 2x160 μg Twice Daily in Adult and Adolescent Asthmatics
Status:
COMPLETED
Status Verified Date:
2014-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
BAI
Brief Summary:
This is a comparison of the efficacy of the Symbicort breath actuated dose inhaler to the Symbicort pressured meter dose inhaler after 12 weeks of a twice a day dose
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None